Gland Pharma Ltd. (GLAND) fundamentals
Gland Pharma Ltd. is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as GLAND (ISIN INE068V01023). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Gland Pharma Ltd. does
Gland Pharma Limited is an India-based generic injectables manufacturer. The Company specializes in sterile injectables, oncology, and ophthalmic, with a specific focus on complex injectables, New Chemical Entities (NCE)-1s, First-to-File products, and 505(b)(2) filings. The Company manufactures a range of dosage formulations, including solutions, suspensions, and lyophilized products. Its product portfolio includes delivery methods such as pre-filled syringes, vials, ampoules, bags, and dry powder injections. It also produces generic injectables in liquid, lyophilized, suspension, and pre-filled syringe forms. Its molecules include Enoxaparin Sodium, Cisplatin, Lacosamide, Rocuronium Bromide, Zoledronic Acid, Vancomycin, and others. Its therapeutic products categories include Anti Malarials, Anti-Infectives, Anti-Neoplastics, Gynecological, Hormones, and others. The Company functions primarily on a business-to-business model. Its subsidiary is Gland Pharma International Pte. Ltd.
Valuation and market data
| Last close | ₹2922.30 |
|---|---|
| Market capitalisation | ₹48,150 crore |
| Enterprise value | ₹45,335 crore |
| P/E (TTM) | 46.87 |
| Price to book | 4.65 |
| Price to sales (TTM) | 4.14 |
| Book value per share | ₹628.64 |
| Dividend yield | 68.44% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Fri Nov 20 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹4,856 crore | ₹1,748 crore | ₹1,300 crore | 78.88 |
| Mar 2025 | ₹4,331 crore | ₹1,466 crore | ₹1,090 crore | 66.15 |
| Mar 2024 | ₹4,334 crore | ₹1,406 crore | ₹1,043 crore | 63.35 |
| Mar 2023 | ₹3,857 crore | ₹1,048 crore | ₹776 crore | 47.12 |
| Mar 2022 | ₹4,625 crore | ₹1,619 crore | ₹1,212 crore | 73.84 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 51.8% |
|---|---|
| Foreign institutions (FII) | 8.7% |
| Mutual funds | 28.2% |
| Other domestic institutions | 2.2% |
| Retail and others | 9.1% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.